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Summary
Background Basal cell carcinoma (BCC) represents the most common nonmelanoma
skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The
World Health Organization distinguishes aggressive and nonaggressive forms, of
which prototypical variants of the latter are primary nodular and superficial BCC.
Objectives To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel con-
taining 5-aminolaevulinic acid) compared with MAL (a cream containing methyl
aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic
therapy (PDT). Noninferiority of the primary efficacy variable (overall patient
complete response 12 weeks after last PDT) would be declared if the mean
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2018) 179, pp309–319 309
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Conflicts of interest
Conflicts of interest statements can be found in the
Appendix.
*Plain language summary available online
DOI 10.1111/bjd.16441
response for BF-200 ALA was no worse than that for MAL, within a statistical
margin of D = 15%.
Methods The study was a randomized, phase III trial performed in Germany and the
U.K. with ongoing 5-year follow-up. Of 281 randomized patients, 138 were treated
with BF-200 ALA and 143 with MAL. Patients received two PDT sessions 1 week
apart. Remaining lesions 12 weeks after the second PDT were retreated. Illumination
was performed with a red light source (635 nm, 37 J cm2). The results shown
include clinical end points and patients’ reassessment 12 months after the last PDT.
The study was registered with EudraCT (number 2013-003241-42).
Results Of the BF-200 ALA-treated patients, 934% were complete responders com-
pared with 918% in the MAL group. The difference of means was 16, with a one-
sided 975% confidence interval of 65, establishing noninferiority (P < 00001).
The results for secondary efficacy parameters were in line with the primary out-
come. Recurrence rates 12 months after the last treatment were ≤ 10%.
Conclusions Treatment of nonaggressive BCC with BF-200 ALA-PDT is highly effec-
tive and well tolerated with proven noninferiority to MAL-PDT. It demonstrates
low recurrence rates after 1 year of follow-up.
What’s already known about this topic?
• Photodynamic therapy (PDT) using BF-200 aminolaevulinic acid (ALA) gel is regis-
tered and highly effective in the treatment of mild-to-moderate actinic keratosis
and field cancerization.
• BF-200 ALA gel was recently approved for the treatment of superficial and/or
nodular basal cell carcinoma (BCC) unsuitable for surgical treatment.
• PDT using methyl aminolaevulinate (MAL) cream is approved for the treatment of
thin or nonhyperkeratotic and nonpigmented actinic keratoses, Bowen disease, and
superficial and nodular BCCs when other therapies are considered less appropriate.
What does this study add?
• BF-200 ALA-PDT is confirmed to be significantly noninferior to MAL-PDT for the
treatment of nonaggressive BCC.
• Treatment-emergent adverse events were comparable between the two patient
groups, with similar or slightly lower recurrence rates for BF-200 ALA gel com-
pared with MAL cream after 12 months.
Basal cell carcinoma (BCC) represents the most common type
of nonmelanoma skin cancer (NMSC) worldwide, affecting
mainly adult (age ≥ 40 years), fair-skinned individuals.1,2 Its
incidence is increasing steadily and is currently estimated at
3–10%.1,3 In the U.S.A., a 50% increase in male patients and
a 20% increase in female patients was observed between two
observational studies in 1977–78 and 1998–99, respectively.4
In Europe, incidence rates increased threefold between 1997
and 2008, and rates are presumed to continue growing.5,6
Worldwide, the highest incidences were reported for Aus-
tralia, showing a 44-fold increase in NMSC between 1985
and 2011, with higher rates in male patients and for BCCs.7
The lifetime risk of developing BCC is estimated at around
30%, increasing to around 40% within 3 years in patients
with a prior BCC.2,6 The ageing population and higher
awareness, along with more frequent diagnosis of skin
tumours and changes in lifestyle, are thought to contribute to
the dramatically increasing numbers of patients and the associ-
ated increase in cost.6 New therapeutic options are thus in the
best interest of the general public.3
Although invasive procedures are the most widely used for
the treatment of BCC, guideline recommendations are vari-
able.5 Cryosurgery has a weaker recommendation, whereas
surgical excision is usually the most appropriate treatment for
BCC.1,5,8,9 Nevertheless, alternative therapeutic concepts must
be considered to overcome the drawbacks associated with
physical measures, notably cosmetic outcome, functional
impairments and/or the need for reconstructive surgery after
the treatment of multiple or larger lesions. This holds particu-
larly true for locations in the face or on the neck, where
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≥ 75% of all BCCs are located.3,6,10 Among topical therapies,
photodynamic therapy (PDT) is considered appropriate for the
treatment of low-risk tumours, such as superficial (s)BCC and
nodular (n)BCC, and for the treatment of large or multiple
lesions.11–20 The advantages of PDT include excellent compli-
ance and short treatment and down time, besides its high
efficacy and superior cosmetic results.
BF-200 ALA is a topically applied nanoemulsion-based gel
that contains 78% 5-aminolaevulinic acid (ALA). The for-
mulation improves the stability of ALA and enhances epider-
mal penetration compared with other formulations.21,22
Thus, the concentration of the active substance could be sig-
nificantly reduced. In the reported clinical study, BF-200
ALA was compared with a cream containing 16% methyl
aminolaevulinic acid (MAL) using a noninferiority trial
design. MAL is approved for the treatment of sBCC and/or
nBCC unsuitable for other available therapies, due to possi-
ble treatment-related morbidity and poor cosmetic outcome.
Clinical studies comparing MAL with surgery or cryotherapy
revealed lesion complete response rates for MAL ranging
between 73% and 97%, always with superior cosmetic out-
come.20,23–25 Both ALA and MAL are essential prodrugs for
the targeted photodestruction of neoplastic cells. They selec-
tively induce accumulation of the photosensitive metabolite
protoporphyrin IX (PpIX) due to these cells’ altered metabo-
lism. Illumination at an appropriate wavelength activates
PpIX and leads to the specific destruction of tumour cells by
reactive oxygen species.26–28
A previous study of BCC using a preliminary ALA
nanoemulsion formulation showed a promising complete
lesion response rate in sBCC of 85% 6 months after a single
PDT treatment,29 confirming the results of the above-men-
tioned studies. In order to compare BF-200 ALA gel and MAL
cream in the treatment of nonaggressive BCC, a study based
on the theory that BF-200 ALA gel is noninferior to MAL
cream (with a noninferiority margin of D = 15) was
designed. Meanwhile, BF-200 ALA was granted a label exten-
sion for the treatment of sBCC and nBCC in the European
Union.
Patients and methods
The study was performed as a randomized, noninferiority,
phase III trial using BF-200 ALA gel and MAL cream at a ratio
of 1 : 1.
The 24 study centres in Germany and the U.K. included
university hospitals, dermatological clinical centres and pri-
vate dermatological practices. The study was approved by
the responsible ethics committees and the appropriate
authorities prior to the start of the study and was performed
according to the national drug laws, the guidelines of good
clinical practice and the Declaration of Helsinki (EudraCT
number 2013-003241-42). The study was sponsored by
Biofrontera Bioscience GmbH. The study design was devel-
oped by the coordinating investigators in cooperation with
the sponsor.
Study medication and illumination
The study medication was produced and released for the clini-
cal study according to good manufacturing practice and rele-
vant regulations. Tubes with either BF-200 ALA gel (Ameluz;
Biofrontera, Leverkusen, Germany) or MAL cream (Metvix or
Metvixia; Galderma, Lausanne, Switzerland) were used in the
marketed 2-g formulations. For illumination, a light-emitting
diode source (BF-RhodoLED; Biofrontera) producing red
light at 635  9 nm was used.30
Study population
Male and female patients (> 18 years of age) diagnosed with
one to three nonaggressive BCCs (05–2 cm in diameter) on
the face/scalp, neck/trunk or extremities were enrolled. A
3-mm punch biopsy taken at screening from each target lesion
had to prove eligibility of nonaggressiveness and a thickness
≤ 2 mm by histological assessment.
Patients with porphyria and photodermatoses, or any intol-
erance to the ingredients of BF-200 ALA gel or MAL cream,
were excluded. Topical treatments possibly affecting the
response to the study treatment were not allowed during the
12 weeks preceding the first PDT or during the study, with
the exception of topical corticosteroids. Starting the use of
substances with phototoxic or photoallergic potential was for-
bidden from 8 weeks prior to and during PDT. Patients
exposed to these medications for > 8 weeks were allowed to
participate if no phototoxic or photoallergic reactions were
observed. Systemic treatments possibly impairing the outcome
were not allowed 1–6 months before (time frame depending
on the substance) or during the study; patients were allowed
to take up to 100 mg acetylsalicylic acid daily for preventive
measures.
Randomization
The randomization schedule was generated by Accovion
GmbH (Eschborn, Germany) using a validated program that
automates the random assignment of treatments to randomiza-
tion numbers. Randomization was performed with a block size
of six. Patient assignment to a group occurred according to
the randomization schedule.
Treatment protocol
The study was conducted using an observer-blind design, as
the drug products display different consistencies in their for-
mulation. The treatment regimen included one obligatory PDT
cycle with two PDT sessions 1 week apart, and a second PDT
cycle in case of remaining lesions 12 weeks after the first
cycle. The clinical observation period lasted up to 12 weeks
after the last PDT, followed by post-treatment observation for
57 months. Recurrence rates after 12 months post-treatment
are included here; later time points will be reported
separately.
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After degreasing and carefully removing scabs, crusts and
exophytic tumour material, either BF-200 ALA gel or MAL
cream was administered to the lesions at about 1-mm thick-
ness. Subsequently, an occlusive light-tight dressing was
placed over the target lesions for the entire incubation period
(3 h  10 min). Thereafter, remnant gel or cream was wiped
off and illumination of the target lesion(s) was performed
immediately.
Efficacy assessment
The clearance of individual lesions was assessed by visual
inspection 4 and 12 weeks after treatments. The primary effi-
cacy parameter was the overall patient complete response rate
12 weeks after the last PDT, defined as the complete clearance
of all treated lesions. Subgroup analyses and analyses of sec-
ondary efficacy parameters (lesion complete response rate
12 weeks after the last PDT, patient complete response rate
12 weeks after the second PDT) were performed according to
the baseline characteristics of the BCCs.
Cosmetic outcome was determined by the investigator
according to skin-quality parameters, as described by Rein-
hold et al.30 Patient satisfaction was assessed 12 weeks after
the last PDT using a four-point scale from very good to
impaired.
Safety and tolerability assessment
Local adverse reactions at the application site were docu-
mented during and after PDT. Symptoms were classified as
mild, moderate or severe. Ranking of the subjective sensations
pain, burning and itching was done by the patient. Pain dur-
ing PDT was assessed with a numerical rating pain scale rang-
ing from 0 (no pain at all) to 10 (worst possible pain). For
the overall adverse event (AE) assessment these data were
transferred to a four-point severity scale (0 none, > 0–3 mild,
4–7 moderate, 8–10 severe). Treatment-emergent AEs (TEAEs)
were defined as all AEs with onset or worsening after the first
treatment with randomized medication until the end of the
clinical observation period. Serious adverse events were docu-
mented and evaluated throughout the study.
Statistical analysis
The method of Farrington and Manning for testing noninferi-
ority of differences of proportions was used to test the pri-
mary hypothesis on a significance level of 25% (one-sided).
A sample size of 115 evaluable patients per treatment group
ensured a power of ≥ 90% for evaluation of the primary effi-
cacy parameter, which was the overall patient complete
response rate 12 weeks after the last PDT. This estimate was
Enrolled
394
MAL
Randomized set 143
Safety analysis set 143
Full analysis set 143
Per protocol set 110
BF-200 ALA
Randomized set 138
Safety analysis set 138
Full analysis set 138
Per protocol set 121
Discontinued = 10 
Patient decision 3
Adverse event 2
Death 1
Other 4
Discontinued = 9
Patient decision 3
Adverse event 1
Other 5
Completed
133
Completed
129
Not randomized =  113
Screening Failure* 104
Patient decision 7
Lost to follow-up 1
Other (stop of
recruitment) 1
Fig 1. Flowchart of patient disposition in the
clinical part of the study. *Initially it was
considered an exclusion criterion if – besides
an eligible basal cell carcinoma (BCC) –
patients had noneligible BCC (all confirmed
by biopsy), which resulted in a high amount
of screening failures. In the course of the
study, the protocol was amended such that
individuals with at least one biopsy-proven,
eligible BCC could be included if the distance
to a noneligible lesion was > 10 cm. The
protocol amendment was not expected to
influence the composition of the enrolled
patient population. MAL, methyl
aminolaevulinate; ALA, aminolaevulinic acid.
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based on an expected response rate of 87% in each treatment
arm and a noninferiority margin of D = 15. Analysis was
performed on the per protocol set; the full analysis set was
presented as supportive analysis. All other data were analysed
descriptively and in an exploratory way.
Recurrence rates during follow-up were calculated for
patients and for lesions with a complete response 12 weeks
after the last PDT according to the primary and secondary effi-
cacy variables. To determine the probability of remaining
cleared up to a particular follow-up visit, life tables were cal-
culated for patients and lesions by multiplying the recurrence
rate at follow-up (Pi) by the initial clearance rate (Pi*CR or
Pi*RCL), as described previously.31
Results
Patients
The clinical observation period took place between January
2014 and November 2015; 1-year follow-up was completed
in August 2016. Of 281 randomized patients (138 patients to
BF-200 ALA gel and 143 patients to MAL cream), 19 patients
prematurely discontinued the clinical part of the study. A
flowchart of the disposition of the patients is presented in Fig-
ure 1. All patients were white. The patient and lesion charac-
teristics are summarized in Table 1.
Efficacy
Overall patient complete response rate
At 12 weeks after the last PDT, 934% (n = 113) of patients
in the BF-200 ALA group showed complete clearance of all
BCC lesions, compared with 918% (n = 101) in the MAL
group (Table 2). The noninferiority test revealed a difference
of means of 16 with a one-sided 975% confidence interval
(CI) of 65% (P < 0001), thus demonstrating statistical
noninferiority of BF-200 ALA gel compared with MAL cream
for the primary efficacy parameter. The robustness of the
results was confirmed by repeating the analyses on the full
analysis set, which displayed a difference in efficacy of 52
(one-sided 975% CI 33; P < 00001), with 899%
(n = 124) of the patients in the BF-200 ALA group and
846% (n = 121) in the MAL group showing complete clear-
ance. More than half of the patients were already completely
cleared 12 weeks after the second PDT session in both treat-
ment arms: 579% in the BF-200 ALA group and 564% in
the MAL group, with overlapping 95% CIs.
With respect to patients with sBCC only, 95% in the BF-
200 ALA group and 96% in the MAL group showed complete
clearance 12 weeks after the last treatment. Patients with only
nBCC displayed clearance rates of 86% with BF-200 ALA and
76% with MAL (Table 2). Further subgroup analyses revealed
clearance rates of 92% for BF-200 ALA and 93% for MAL in
patients with only one BCC lesion, whereas clearance rates for
patients with two or more lesions were 100% and 88%,
respectively. Differences between treatments are displayed in
Figure 2.
One year after the last treatment, overall patient relapse
occurred to a similar extent in both groups (84% for BF-200-
ALA, 85% for MAL). Thus, of the full responders 12 weeks
after the last PDT, > 91% remained fully cleared 12 months
after PDT. In patients with sBCC only, the recurrence rate
dropped to 7% for BF-200 ALA and to 8% for MAL. A larger
difference was observed for patients with nBCC only, with 7%
of patients in the BF-200 ALA group and 14% in the MAL
group relapsing within 12 months (Table 2).
Considering the patients who were still clear at the 1-year
follow-up, the initial difference of 16% between both treat-
ments was maintained due to the low recurrence rates. From
the perspective of pretreatment, an overall patient clearance
(Pi*CR) of 858% was calculated for the BF-200 ALA group
compared with 844% for the MAL group. These values spread
to 883% vs. 890% for sBCC, and to 810% vs. 663% for
nBCC in the BF-200 ALA and MAL groups, respectively, at the
1-year follow-up (Table 2).
Table 1 Summary of patient and basal cell carcinoma (BCC) lesion
characteristics before treatment
Variable
MAL cream
(n = 110)
BF-200 ALA gel
(n = 121)
Sex, n (%)
Male 55 (500) 76 (628)
Female 55 (500) 45 (372)
Age (years),
mean  SD
665  115 673  116
Fitzpatrick skin type, n (%)
I–III 98 (891) 109 (901)
IV–VI 12 (109) 12 (99)
BCC lesions at
baseline
127 148
BCC lesions at
baseline per patient,
mean  SD
12  039 12  049
BCC lesions at baseline per patient, n (%)
1 94 (855) 98 (810)
≥ 2 16 (145) 23 (190)
BCC subtype, n (%)a
nBCC only 21 (191) 21 (174)
sBCC only 83 (755) 95 (785)
Others 6 (55) 5 (41)
Location of lesions, n (%)
Face/scalpb 17 (134) 17 (115)
Neck/trunk 87 (685) 97 (655)
Extremities 23 (181) 34 (230)
Thickness of BCC
lesions overall (mm),
mean  SD
046  036 041  032
Data are presented for the per protocol set. MAL, methyl amino-
laevulinate; ALA, aminolaevulinic acid; nBCC, nodular BCC;
sBCC, superficial BCC. aBased on patients. bOnly one lesion was
located on the scalp.
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Lesion complete response rate
The rate of completely cleared individual lesions assessed
12 weeks after the last PDT was 946% (n = 148) in the BF-
200 ALA group and 929% (n = 127) in the MAL group. Sub-
group analyses revealed numerical differences in lesion com-
plete response rates when comparing BF-200 ALA vs. MAL
treatment of sBCC (96% vs. 97%), of nBCC (89% vs. 79%),
on the face/scalp (82% vs. 71%), on the neck/trunk (98% vs.
97%) and on the extremities (91% vs. 96%), but without sta-
tistical significance (Table 3). It is of note that there is some
variation in the group sizes per treatment area, as recruitment
was not stratified for this parameter (Table 1).
From the cleared lesions observed during follow-up, 67%
in the BF-200 ALA group and 82% in the MAL group
relapsed within 12 months after the last PDT. Thus, of all
lesions that had been clinically assessed as fully cleared after
3 months, 933% treated with BF-200 ALA and 918% treated
with MAL were still clear at this time point. Regarding the
sBCC and nBCC lesions, 5% and 9% of lesions, respectively, in
the BF-200 ALA group, and 8% and 10%, respectively, in the
MAL group relapsed within 1 year after the last PDT. One-year
recurrence rates for the different locations were 8% (face/
scalp), 7% (neck/trunk) and 6% (extremities) in the BF-200
ALA group. The corresponding values in the MAL group were
18%, 8% and 5%, respectively (Table 3).
Table 2 Patient clearance and recurrence rates
Subgroup and
assessment time
point after last PDT
MAL cream BF-200 ALA gel
Completely
cleared, n/N (%)
Recurrent,
n (%)
Pi
(%)
Pi*CR
(%)
Completely
cleared, n/N (%)
Recurrent,
n (%)
Pi
(%)
Pi*CR
(%)
Overall
EOS (12 weeks) 101/110 (918) n.a. 100 918 113/121 (934) n.a. 100 934
95% CI 846–960 870–969
FU2 (12 months) 86/94a (915) 8 (85) 919 844 98/107a (916) 9 (84) 919 858
95% CI 834–960 40–166 842–958 42–158
With sBCC only
EOS (12 weeks) 80/83 (96) n.a. 100 964 90/95 (95) n.a. 100 947
95% CI 891–991 876–980
FU2 (12 months) 69/75a (92) 6 (8) 923 890 81/87a (93) 6 (7) 933 883
95% CI 828–967 33–172 850–972 28–150
With nBCC only
EOS (12 weeks) 16/21 (76) n.a. 100 762 18/21 (86) n.a. 100 857
95% CI 525–900 626–962
FU2 (12 months) 12/14a (86) 2 (14) 871 663 14/15a (93) 1 (7) 944 810
95% CI 562–975 25–438 660–997 03–340
Data are presented for the per protocol set. ALA, aminolaevulinic acid; BCC, basal cell carcinoma; CI, confidence interval; EOS, end of clinical
study (12 weeks after the last PDT); FU2, follow-up 2 (12 months after the last treatment); MAL, methyl aminolaevulinate; n.a., not applica-
ble; nBCC, nodular BCC; PDT, photodynamic therapy; Pi, probability of patients remaining fully cleared until the current visit; Pi*CR, esti-
mated rate of patient clearance at the current visit relative to the number of patients pretreatment; sBCC, superficial BCC. aComplete
responders 12 weeks after the last PDT with data at 1-year follow-up
Paents with ≥ 2 lesions
Paents with 1 lesion
Paents with nBCC only
Paents with sBCC only
Complete responder rate
-15 -10 -5 0 5 10 15
Treatment diﬀerence for paent complete response
(BF-200 ALA treatment minus MAL treatment)
BF-200 ALA TREATMENT WORSE BF-200 ALA TREATMENT BETTER
Δ
Fig 2. Treatment efficacy: overall patient
complete response rate and subgroup analyses
for the per protocol set. A patient was
considered a complete responder if all treated
lesions were cleared 12 weeks after the last
session of photodynamic therapy. Error bars
represent one-sided 975% confidence
intervals of the difference between BF-200
aminolaevulinic acid (ALA) and methyl
aminolaevulinate (MAL) treatment. The blue
dashed line at D = 15 indicates the
noninferiority margin for the primary efficacy
variable; the blue region to the right of
D = 15 indicates the zone of noninferiority.
nBCC, nodular basal cell carcinoma; sBCC,
superficial basal cell carcinoma.
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Relative to the lesion number at baseline, the estimate for
lesions to be cleared 1 year after the last treatment (Pi*RLC)
was 884% in the BF-200 ALA group and 856% in the MAL
group. For the main BCC subtypes, sBCC and nBCC, the
respective estimates were 907% and 819% in the BF-200
ALA group compared with 895% and 713% in the MAL
group. Thus, the initial differences between the efficacies were
maintained throughout follow-up, supporting an advantage
for BF-200 ALA, especially in nBCC treatment (Table 3).
Cosmetic outcome
The overall cosmetic outcome was rated as ‘very good or
good’ by 60% of the patients treated with BF-200 ALA and by
49% of the patients treated with MAL (excluding those patients
without skin-quality impairment at baseline) 12 weeks after
the last PDT (Table 4). The favourable assessment of ‘very
good or good’ increased during follow-up to 73% for BF-200
ALA and to 68% for MAL 1 year after the last PDT.
Patient satisfaction
The vast majority of patients in both groups rated their satis-
faction as ‘very good or good’ (87% of patients in the BF-200
ALA group and 86% in the MAL group). This high satisfaction
was maintained during the 1-year follow-up: 97% of BF-200
ALA- and 99% of MAL-treated patients were still satisfied with
PDT. No patient assessed their satisfaction as impaired at either
time point.
Safety and tolerability
The frequencies and severities of TEAEs were within the
ranges expected, given a population of mainly elderly patients,
Table 3 Lesion clearance and recurrence rates
Subgroup and
assessment time
point after last PDT
MAL cream BF-200 ALA gel
Completely cleared,
n/N (%)
Recurrent,
n (%)
Pi
(%)
Pi*RLC
(%)
Completely cleared,
n/N (%)
Recurrent,
n (%)
Pi
(%)
Pi*RLC
(%)
Overall
EOS 118/127 (929) n.a. 100 929 140/148 (946) n.a. 100 946
95% CI 866–965 893–975
FU2 101/110a (918) 9 (82) 922 856 125/134a (933) 9 (67) 935 884
95% CI 846–960 40–154 873–967 33–127
sBCC
EOS 95/98 (97) n.a. 100 969 114/119 (96) n.a. 100 958
95% CI 907–992 900–984
FU2 82/89a (92) 7 (8) 924 895 105/111a (95) 6 (5) 947 907
95% CI 839–965 35–161 881–976 22–119
nBCC
EOS 22/28 (79) n.a. 100 786 25/28 (89) n.a. 100 893
95% CI 585–910 706–972
FU2 18/20a (90) 2 (10) 907 713 20/22a (91) 2 (9) 917 819
95% CI 669–982 18–331 694–984 16–306
BCC face/scalpb
EOS 12/17 (71) n.a. 100 706 14/17 (82) n.a. 100 824
95% CI 440–886 558–953
FU2 9/11a (82) 2 (18) 826 583 12/13a (92) 1 (8) 926 763
95% CI 478–968 32–522 621–996 04–379
BCC neck/trunk
EOS 84/87 (97) n.a. 100 966 95/97 (98) n.a. 100 979
95% CI 895–991 920–996
FU2 73/79a (92) 6 (8) 927 895 84/90a (93) 6 (7) 936 917
95% CI 836–969 31–164 855–973 27–145
BCC extremities
EOS 22/23 (96) n.a. 100 957 31/34 (91) n.a. 100 912
95% CI 760–998 752–977
FU2 19/20a (95) 1 (5) 953 912 29/31a (94) 2 (6) 935 853
95% CI 731–997 03–269 772–989 11–228
Data are presented for the per protocol set. ALA, aminolaevulinic acid; BCC, basal cell carcinoma; CI, confidence interval; EOS, end of clinical
study (12 weeks after the last PDT); FU2, follow-up 2 (12 months after the last treatment); MAL, methyl aminolaevulinate; n.a., not applica-
ble; nBCC, nodular BCC; PDT, photodynamic therapy; Pi, probability of lesions remaining cleared up to the current visit; Pi*RLC, estimated
rate of lesion clearance at the current visit relative to the number of lesions pretreatment; sBCC, superficial BCC. aBCC lesions cleared
12 weeks after the last PDT with data at 1-year follow-up. bOnly one lesion was located on the scalp.
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the nature of the underlying disease, and the known safety
profile of PDT with BF-200 ALA gel and MAL cream, which is
related to the mode of action (Table 5). Frequencies were
comparable between the groups and revealed no statistically
significant differences. The most commonly reported TEAEs in
both groups were local reactions at the application site (pain,
erythema, pruritus and oedema). The majority of related TEAEs
were of mild-to-moderate intensity. Ten (36%) patients
reported serious TEAEs during the clinical part of the study,
none of which was assessed as being related to the study medi-
cation. Only four patients discontinued the study prematurely
(Table 5). Local pain experienced during PDT was assessed for
each PDT session (on a numerical rating pain scale) and
showed similar values for both treatments (Table 6).
Discussion
Recent guidelines for BCC treatment discuss the choice of use-
ful therapies based on the prognosis rather than on the clinical
or histological subtype. For nonaggressive BCC displaying
good-to-intermediate prognosis, PDT is regarded as a highly
appropriate treatment option, providing high efficacy and
favourable cosmetic outcome without significant functional
constraints.5,8,9
In the presented study, high overall response rates of
> 90% were obtained for both medications 12 weeks after the
last PDT, with a patient complete response rate of 934% for
BF-200 ALA vs. 918% for MAL. Even after the first PDT cycle
considerably more than 50% of the patients were clinically
clear of BCC in both groups. Statistical analysis revealed that
BF-200 ALA gel was noninferior to the registered MAL cream.
The current study was designed to show noninferiority of
BF-200 ALA in comparison with MAL. However, superiority
of BF-200 ALA had previously been demonstrated in a phase
III trial treating actinic keratosis in 571 randomized patients.32
In particular, the efficacy for thicker lesions or more difficult-
to-treat lesions on the scalp was higher with BF-200 ALA.21,32
In the present trial, similar findings were seen for nBCC
Table 4 Cosmetic outcome 12 weeks after the last photodynamic therapy (PDT) and 1-year follow-up
MAL cream BF-200 ALA gel
EOS (n = 74) 1y FU (n = 57)a EOS (n = 70) 1 year (n = 56)a
Very good, n (%) 16 (22) 17 (30) 28 (40) 20 (36)
95% CI 132–330 188–436 287–524 237–497
Good, n (%) 20 (27) 22 (39) 14 (20) 21 (38)
95% CI 177–388 263–524 117–316 252–515
Satisfactory, n (%) 24 (32) 8 (14) 16 (23) 8 (14)
95% CI 223–444 67–263 140–347 68–268
Unsatisfactory, n (%) 9 (12) 6 (11) 8 (11) 2 (4)
95% CI 61–223 44–222 54–218 06–134
Impaired, n (%) 5 (7) 4 (7) 4 (6) 5 (9)
95% CI 25–157 23–178 18–147 33–204
Data are presented for the per protocol set. Patients lacking compromised skin at baseline were excluded. Cosmetic outcome was calculated
on the basis of skin-quality assessment.30 Parameters (skin surface, pigmentation, degree of scarring and atrophy) were rated on a four-point
scale from none to severe at baseline, at the end of the clinical observation period 12 weeks after the last PDT, and during follow-up. 1y
FU, follow-up 12 months after the last PDT; ALA, aminolaevulinic acid; CI, confidence interval; EOS, end of clinical study (12 weeks after
the last PDT); MAL, methyl aminolaevulinate. aOnly complete responders were considered and patients with recurrent basal cell carcinoma
lesions were excluded.
Table 5 Overview of treatment-emergent adverse events (TEAEs)
TEAE category
MAL cream
(n = 143)
BF-200 ALA gel
(n = 138)
Patients with TEAEs 143 (100) 138 (100)
Patients with relateda TEAEs 143 (100) 138 (100)
Patients with serious TEAEs 7 (49) 3 (22)
Patients with relateda
serious TEAEs
0 0
Patients with TEAEs leading to
death
1 (07) 0
Patients with relateda
TEAEs leading to death
0 0
Patients with TEAEs leading to
study withdrawal
2 (14) 1 (07)
Patients with relateda TEAEs
leading to study withdrawal
1 (07) 1 (07)
Patients with TEAEs rated as local
skin reaction
130 (909) 122 (884)
Patients with relateda TEAEs
rated as local skin reaction
130 (909) 121 (877)
Patients with TEAEs rated as
discomfort
143 (100) 136 (986)
Patients with relateda TEAEs
rated as discomfort
143 (100) 136 (986)
Patients with pain 143 (100) 134 (971)
Patients with pain considered
relateda to study treatment
143 (100) 134 (971)
Values are the number (%) of patients. Data are presented for
the safety population and comprise TEAEs until 12 weeks after
the last photodynamic therapy. aConsidered possibly, probably
or definitely related to study treatment. MAL, methyl aminolae-
vulinate; ALA, aminolaevulinic acid.
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lesions, for which a higher proportion of response was
revealed with BF-200 ALA (89%) than with MAL (79%); this
was maintained during the 1-year follow-up period. Previous
results reported by Rhodes et al.23 showed high efficacies of
MAL-PDT in the treatment of nBCC when compared with sur-
gery (91% vs. 96%, P = 015). The differences for MAL may
be due to different lesion preparations in the studies. Lower
efficacy rates for nBCC were also described in the survey of
Peng et al.33 using extemporaneous ALA formulations. Based
on 12 ALA-PDT studies with 208 lesions there was a weighted
average complete response of 53%. The high efficacy observed
for BF-200 ALA in the present study is presumed to be due to
the enhanced skin penetration of this formulation.
For sBCC lesions, where skin penetration is less relevant,
both medications displayed very similar efficacies (≥ 95%).
These results exceed the weighted clearance rate of 87% calcu-
lated on the basis of 12 sBCC studies with 826 lesions treated
with ALA-PDT.33 Again, this may depend on the different for-
mulations and treatment protocols.29 In a previous study com-
paring MAL-PDT with surgery for sBCC, noninferiority was
demonstrated for MAL-PDT with clearance rates of 922%
(MAL) vs. 992% (surgery).20 A meta-analysis of 28 studies
including various topical treatments showed clearance rates of
79% for MAL-PDT compared with 862% for imiquimod, and
indicated tumour-free 1-year survival rates of 84% and
873%, respectively.11
An additional study by Arits et al.34 reported clearance rates
for sBCC of 900% with imiquimod, 879% with 5-fluoroura-
cil and 842% with MAL after 3 months. In that study, only
one PDT cycle was applied for MAL treatment, which is not
in agreement with its label, while all other drugs were used
according to their approved posology. However, after
12 months, the overall estimates of treatment success were
calculated as 872%, 801% and 725% for imiquimod, 5-
fluorouracil and MAL, respectively. In the present study, the
corresponding estimates were 883% for BF-200 ALA gel and
890% for MAL cream (Table 2). As these patients will be fol-
lowed up for another 4 years, future recurrence rates will
provide additional insight into the efficacy of BF-200 ALA-
PDT.
Overall, high efficacy rates and low recurrence rates in
the treatment of nonaggressive BCC were achieved with BF-
200 ALA-PDT and MAL-PDT. The local adverse events
observed in this study are well known for PDT and are
caused by the underlying mode of action. No difference in
adverse events became apparent between the treatments.
Several European guidelines have rated PDT in the categories
quality of evidence I, and strength of recommendation A
(for sBCC) or B (for nBCC).5,8,35 The present study re-
inforces the high ranking of PDT in the treatment of BCC.
With BF-200 ALA, an excellent alternative for thin non-
aggressive BCC is provided.
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